Abstract
Executive Summary
Cancer of the prostate is the second most frequently diagnosed cancer in men
in the US. The prostate cancer market is reaching maturity, and major players`
sales have been eroded by the launch of various LHRH agonist depot
formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have
also seen a significant proportion of physicians switching to alternatives.
Establishing the optimal timing of antihormonal therapy will provide the key
to market growth.
There are today no less than 280 therapeutics targeting prostate cancer, from
early preclinical to marketed drugs. Prostate Cancer Drug Pipeline Update
lists all drugs and gives you a progress analysis on each one of them.
Identified drugs are linked to more than 160 different targets. These targets
are further categorized on the CD-ROM by 51 classifications of molecular
function and with pathway referals to BioCarta, KEGG and NetPath. Read more
below on how the Prostate Cancer Drug Pipeline Update is organized.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug
development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click
from inside the application and you may search the World Wide Web and PubMed
for any drug.
View Cart
